discontinuation-bi-1467335-diabetic-retinopathy

Boehringer Ingelheim discontinues development of BI 1467335 for Diabetic RetinopathyBI 1467335 was acquired from Pharmaxis in 2015 as part of Boehringer Ingelheim ’s growing Retinal Health R&D pipeline portfolioBoehringer Ingelheim has terminated the agreement with Pharmaxis with 90 days ’ notice during which time Pharmaxis can request return of all existing data and intellectual property.Boehringer Ingelheim will continue to advance its comprehensive portfolio of next generation retinal therapy approachesPharmaxis will continue its development of small molecule amine oxidase inhibitors with a phase 2 study in myelofibrosis due to commence later this year
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news